ZBTB46 and lung carcinoma: As suggested in Fig. 5, ZBTB46 expression was significantly positively correlated with VSIR (Spearman’s r = 0.375, p < 0.001), PD1 (Spearman’s r = 0.345, p < 0.001), LILRB2 (Spearman’s r = 0.340, p < 0.001), CTLA-4 (Spearman’s r = 0.328, p < 0.001), TIGIT (Spearman’s r = 0.326, p < 0.001), SIRPA (Spearman’s r = 0.315, p < 0.001), HAVCR2 (Spearman’s r = 0.295, p < 0.001), BTLA (Spearman’s r = 0.287, p < 0.001) and PD-L1 (Spearman’s r = 0.105, p < 0.001) in lung cancer.